Planning for Third-Line Therapy and Treatment Rechallenge in mCRC

In this episode, “Planning for Third-Line Therapy and Treatment Rechallenge in mCRC,” the panel explores how clinicians anticipate the transition to later-line care and determine whether previously used therapies may have a role again. Dr. Parseghian explains that she begins thinking about third-line therapy early, often once a patient is established on second-line treatment. A consistent rise in CEA, mixed response on imaging, slow growth on serial scans, increasing symptoms, or cumulative toxicity may prompt more active planning. Rather than changing therapy for a tumor marker increase alone, she may obtain imaging sooner and begin evaluating later-line options before performance status or organ function deteriorates.

The discussion also examines molecular reassessment. Dr. Parseghian uses circulating tumor DNA before third-line treatment, particularly in patients previously exposed to anti-EGFR or BRAF-directed therapy. Acquired resistance mutations may make an immediate rechallenge less likely to succeed, while allowing time off treatment may permit resistant clones to decline.

Dr. Strickler then distinguishes treatment reintroduction from true rechallenge. A regimen stopped because of tolerability rather than progression may still retain activity when brought back later. In contrast, a therapy discontinued after true resistance requires more caution and may benefit from molecular reassessment before reconsideration. The episode highlights how later-line planning increasingly depends on understanding why earlier therapies were stopped, how resistance evolves, and whether previously effective treatments can be revisited.

The next episode in this series, “Unanswered Questions in First- and Second-Line mCRC Care,” examines evidence gaps that continue to influence treatment duration, sequencing, and biomarker-driven care.